News — PAI-1

As the year 2023 ends, we at Innovative Research want to thank you for your continued support and trust in our products and services. We are proud to be your partner in advancing scientific knowledge and innovation. To show our appreciation, we have prepared some amazing end-of-year promotions that you don’t want to miss. These promotions are designed to help you save time, money, and resources in your lab, while providing you with the highest quality biological samples and reagents for your research needs. Here are the 5 end-of-year promotions that you can take advantage of right now: Ready-to-Ship Repository:...

A genetic mutation in SERPINE1, the gene responsible for Plasminogen Activator Inhibitor-1 (PAI-1), seems to have ties back to leading a longer, healthier life. While complete PAI-1 deficiency can lead to a life-threatening clotting disorder, individuals who were heterozygous for this mutation seem to enjoy an extended lifespan on average.

New research validates the PAI-1 knockout mouse as a preclinical genetic model of human depression, while demonstrating that this knockout also serves as a model for antidepressant resistance. Not only that, but this new research shows PAI-1 is involved in depression separately from the tPA-BDNF axis. As a result, PAI-1 could be a novel target for developing new treatments for major depressive disorder.

Plasminogen Activator Inhibitor 1 (PAI-1) is a key component of fibrinolysis, the process by which the body is able to break apart a cross-linked fibrin clot. As an inhibitor of both tPA and uPA, PAI-1 is the primary inhibitor among the plasminogen activators and plays an important role in allowing appropriate clotting to occur. PAI-1 also plays a role in different conditions and diseases.